Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women With Hormone Receptor-Positive Advanced Breast Cancer.

Trial Profile

Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women With Hormone Receptor-Positive Advanced Breast Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Letrozole (Primary) ; Tamoxifen (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results of pooled-analysis (n=749) using data from two randomized trials (LEA and CALGB 40503), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results of a genome-wide association study (n=210) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Results assessing risk factors for toxicity presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top